Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource (B-SCR-MM)
Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
Sponsor: Ohio State University Comprehensive Cancer Center
A observational or N/A phase clinical study on AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance, this trial is actively recruiting participants. The trial is conducted by Ohio State University Comprehensive Cancer Center and has accumulated 11 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Feb 2025 — Present [monthly]
Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Nov 2023 — Jul 2024 [monthly]
Recruiting
-
Jun 2022 — Nov 2023 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Recruiting
-
Feb 2020 — Jan 2021 [monthly]
Recruiting
-
Jun 2018 — Feb 2020 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Mar 2018 [monthly]
Recruiting NA
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ohio State University Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .